Clinical Gastroenterology and Hepatology最新文献

英文中文

Elsewhere in the AGA Journals

IF 11.6 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Clinical Gastroenterology and Hepatology

Pub Date : 2025-01-01 DOI: 10.1016/S1542-3565(24)01018-8

引用次数: 0

Features of Gastrointestinal Strongyloidiasis Hyperinfection: Endoscopy and Histopathology 胃肠道斯特龙线虫病高感染的特征：内窥镜和组织病理学。

IF 11.6 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Clinical Gastroenterology and Hepatology

Pub Date : 2025-01-01 DOI: 10.1016/j.cgh.2024.06.021

Udit Asija , Hanna Blaney , Sheila Kumar

引用次数: 0

Antibiotic Exposure and Risk of New-Onset Inflammatory Bowel Disease: A Systematic Review and Dose-Response Meta-Analysis 抗生素暴露与新发炎症性肠病的风险：系统回顾与剂量反应荟萃分析。

IF 11.6 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Clinical Gastroenterology and Hepatology

Pub Date : 2025-01-01 DOI: 10.1016/j.cgh.2024.02.010

Ruqiao Duan , Cunzheng Zhang , Gaonan Li , Jun Li , Liping Duan

Background & Aims

The association between antibiotic exposure and inflammatory bowel disease (IBD) remains controversial, especially whether there is a dose-response relationship. We aimed to conduct a systematic review and meta-analysis to thoroughly evaluate the risk of new-onset IBD associated with antibiotic exposure.

Methods

Four databases were searched from their inception to September 30, 2023 for all relevant studies. The risk estimates were pooled together using random-effects models, and pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated, stratified by IBD subtype, age, exposure period, study type, and antibiotic classes. Dose-response relationship between the number of antibiotic prescriptions and IBD risk was assessed using generalized least squares regression analysis.

Results

Twenty-eight studies involving 153,027 patients with IBD were included. Antibiotic exposure was significantly associated with an increased risk of new-onset IBD for prescription-based studies (pooled OR, 1.41; 95% CI, 1.29–1.53) and for questionnaire-based studies (pooled OR, 1.35; 95% CI, 1.08–1.68). This association existed for both Crohn’s disease and ulcerative colitis, as well as in children and adults for prescription-based studies. The majority of antibiotic classes were associated with an increased IBD risk, with metronidazole (OR, 1.70; 95% CI, 1.38–2.10) and quinolones (OR, 1.56; 95% CI, 1.37–1.77) having relatively higher risk estimates. A positive nonlinear dose-response association was observed between the number of antibiotic prescriptions and IBD risk.

Conclusions

Antibiotic exposure was significantly associated with an increased risk of new-onset IBD, and a positive nonlinear dose-response relationship was observed. Antibiotic stewardship may be important for reducing IBD risk.

背景和目的：抗生素暴露与炎症性肠病（IBD）之间的关系仍存在争议，尤其是是否存在剂量反应关系。我们旨在进行一项系统回顾和荟萃分析，以全面评估与抗生素暴露相关的新发 IBD 风险：方法：我们在四个数据库中检索了从开始到 2023 年 9 月 30 日的所有相关研究。采用随机效应模型对风险估计值进行了汇总，并按IBD亚型、年龄、暴露期、研究类型和抗生素类别计算了汇总的几率比（OR）和95%置信区间（CI）。使用广义最小二乘法回归分析评估了抗生素处方数量与 IBD 风险之间的剂量-反应关系：结果：共纳入28项研究，涉及153027名IBD患者。在基于处方的研究（汇总 OR = 1.41，95% CI 1.29-1.53）和基于问卷的研究（汇总 OR = 1.35，95% CI 1.08-1.68）中，抗生素暴露与新发 IBD 风险的增加明显相关。在基于处方的研究中，克罗恩病和溃疡性结肠炎以及儿童和成人都存在这种关联。大多数抗生素类别都与 IBD 风险增加有关，其中甲硝唑（OR = 1.70，95% CI 1.38-2.10）和喹诺酮类（OR = 1.56，95% CI 1.37-1.77）的风险估计值相对较高。抗生素处方数量与 IBD 风险之间存在正向非线性剂量反应关系：结论：抗生素暴露与新发 IBD 风险的增加密切相关，并观察到正向非线性剂量-反应关系。抗生素管理对于降低 IBD 风险可能很重要。

{"title":"Antibiotic Exposure and Risk of New-Onset Inflammatory Bowel Disease: A Systematic Review and Dose-Response Meta-Analysis","authors":"Ruqiao Duan , Cunzheng Zhang , Gaonan Li , Jun Li , Liping Duan","doi":"10.1016/j.cgh.2024.02.010","DOIUrl":"10.1016/j.cgh.2024.02.010","url":null,"abstract":"<div><h3>Background & Aims</h3><div>The association between antibiotic exposure and inflammatory bowel disease (IBD) remains controversial, especially whether there is a dose-response relationship. We aimed to conduct a systematic review and meta-analysis to thoroughly evaluate the risk of new-onset IBD associated with antibiotic exposure.</div></div><div><h3>Methods</h3><div>Four databases were searched from their inception to September 30, 2023 for all relevant studies. The risk estimates were pooled together using random-effects models, and pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated, stratified by IBD subtype, age, exposure period, study type, and antibiotic classes. Dose-response relationship between the number of antibiotic prescriptions and IBD risk was assessed using generalized least squares regression analysis.</div></div><div><h3>Results</h3><div>Twenty-eight studies involving 153,027 patients with IBD were included. Antibiotic exposure was significantly associated with an increased risk of new-onset IBD for prescription-based studies (pooled OR, 1.41; 95% CI, 1.29–1.53) and for questionnaire-based studies (pooled OR, 1.35; 95% CI, 1.08–1.68). This association existed for both Crohn’s disease and ulcerative colitis, as well as in children and adults for prescription-based studies. The majority of antibiotic classes were associated with an increased IBD risk, with metronidazole (OR, 1.70; 95% CI, 1.38–2.10) and quinolones (OR, 1.56; 95% CI, 1.37–1.77) having relatively higher risk estimates. A positive nonlinear dose-response association was observed between the number of antibiotic prescriptions and IBD risk.</div></div><div><h3>Conclusions</h3><div>Antibiotic exposure was significantly associated with an increased risk of new-onset IBD, and a positive nonlinear dose-response relationship was observed. Antibiotic stewardship may be important for reducing IBD risk.</div></div>","PeriodicalId":10347,"journal":{"name":"Clinical Gastroenterology and Hepatology","volume":"23 1","pages":"Pages 45-58.e15"},"PeriodicalIF":11.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139995788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Postinfectious Disorders of Gut–Brain Interaction: A Brainstorming Story 感染后肠道与大脑互动失调：一个头脑风暴的故事

IF 11.6 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Clinical Gastroenterology and Hepatology

Pub Date : 2025-01-01 DOI: 10.1016/j.cgh.2024.05.002

Christian Lambiase, Massimo Bellini, Giuseppe Chiarioni

引用次数: 0

Association Between Deep Sedation and Risk of Post-colonoscopy Colorectal Cancer: Swedish Register Data 2007-2016 深度镇静与结肠镜检查后患结直肠癌风险之间的关系：2007-2016年瑞典登记数据

IF 11.6 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Clinical Gastroenterology and Hepatology

Pub Date : 2025-01-01 DOI: 10.1016/j.cgh.2024.06.042

Anna Forsberg, Linnea Widman, Anna Andreasson

引用次数: 0

Blue Notes 蓝色笔记。

IF 11.6 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Clinical Gastroenterology and Hepatology

Pub Date : 2025-01-01 DOI: 10.1016/j.cgh.2024.10.007

Charles J. Kahi MD, MS, AGAF

引用次数: 0

Re-evaluating the Proposed Association Between Vonoprazan and Gastric Cancer Following Eradication of H. pylori Infection 重新评估根除幽门螺杆菌感染后vonoprazan与胃癌之间的关联。

IF 11.6 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Clinical Gastroenterology and Hepatology

Pub Date : 2025-01-01 DOI: 10.1016/j.cgh.2024.04.015

Colin W. Howden, William D. Chey, Shailja C. Shah

引用次数: 0

Risk of De Novo Barrett’s Esophagus Post Sleeve Gastrectomy: A Systematic Review and Meta-Analysis of Studies With Long-Term Follow-Up 袖带胃切除术后新发巴雷特食管病的风险：对长期随访研究的系统回顾和荟萃分析。

IF 11.6 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Clinical Gastroenterology and Hepatology

Pub Date : 2025-01-01 DOI: 10.1016/j.cgh.2024.06.041

Saurabh Chandan , Shahab R. Khan , Smit S. Deliwala , Dushyant S. Dahiya , Babu P. Mohan , Daryl Ramai , Syed M. Saghir , Banreet S. Dhindsa , Lena L. Kassab , Antonio Facciorusso , Kalyana Nandipati , Dennis Yang , Douglas G. Adler

Background & Aims

Sleeve gastrectomy (SG) is one of the most commonly performed bariatric procedures worldwide. Gastroesophageal reflux disease (GERD) is a major concern in patients undergoing SG and is a risk factor for Barrett’s esophagus (BE). We conducted a systematic review and meta-analysis to assess the incidence of and analyze predictive factors for post-SG BE.

Methods

A comprehensive literature search was conducted in April 2024, for studies reporting on incidence of BE, erosive esophagitis (EE), and hiatal hernia (HH) post-SG. Primary outcomes were post-SG pooled rates of de novo BE, EE, GERD symptoms, proton pump inhibitor use, and HH. Meta-regression analysis was performed to assess if patient and post-SG factors influenced the rates of post-SG BE.

Results

Nineteen studies with 2046 patients (79% females) were included. Mean age was 42.2 years (standard deviation, 11.1) and follow-up ranged from 2 to 11.4 years. The pooled rate of de novo BE post-SG was 5.6% (confidence interval, 3.5–8.8). Significantly higher pooled rates of EE (risk ratio [RR], 3.37], HH (RR, 2.09), GER/GERD symptoms (RR, 3.32), and proton pump inhibitor use (RR, 3.65) were found among patients post-SG. GER/GERD symptoms post-SG positively influenced the pooled BE rates, whereas age, sex, body mass index, post-SG EE, and HH did not.

Conclusions

Our analysis shows that SG results in a significantly increased risk of de novo BE and higher rates of EE, proton pump inhibitor use, and HH. Our findings suggest that clinicians should routinely screen patients with SG for BE and future surveillance intervals should be followed as per societal guidelines.

背景：袖带胃切除术（SG）是全球最常见的减肥手术之一。胃食管反流病（GERD）是接受袖带胃切除术的患者最关心的问题，也是导致巴雷特食管（BE）的一个危险因素。我们进行了一项系统回顾和荟萃分析，以评估 SG 术后 BE 的发生率并分析其预测因素：我们于 2024 年 4 月进行了一次全面的文献检索，以获取有关 SG 术后 BE、侵蚀性食管炎 (EE) 和裂孔疝 (HH) 发病率的研究报告。主要研究结果为手术后新发 BE、EE、胃食管反流症状、质子泵抑制剂 (PPI) 使用和 HH 的总发生率。进行了元回归分析，以评估患者和SG后因素是否会影响SG后BE的发生率：共纳入 19 项研究，2046 名患者（79% 为女性）。平均年龄为 42.2 岁（SD 11.1），随访时间从 2 年到 11.4 年不等。SG术后新发BE的汇总率为5.6%（CI为3.5-8.8）。SG术后患者的EE[风险比（RR）3.37]、HH[RR 2.09]、胃食管反流/胃食管返流症状[RR 3.32]和PPI使用[RR 3.65]的汇总率明显更高。SG后胃食管反流/胃食管返流症状对汇总的BE率有积极影响，而年龄、性别、体重指数、SG后EE和HH则没有影响：我们的分析表明，SG 会导致新发 BE 风险显著增加，EE、PPI 使用和 HH 发生率较高。我们的研究结果表明，临床医生应该对 SG 患者进行 BE 常规筛查，并根据社会指南确定今后的监测间隔时间。

{"title":"Risk of De Novo Barrett’s Esophagus Post Sleeve Gastrectomy: A Systematic Review and Meta-Analysis of Studies With Long-Term Follow-Up","authors":"Saurabh Chandan , Shahab R. Khan , Smit S. Deliwala , Dushyant S. Dahiya , Babu P. Mohan , Daryl Ramai , Syed M. Saghir , Banreet S. Dhindsa , Lena L. Kassab , Antonio Facciorusso , Kalyana Nandipati , Dennis Yang , Douglas G. Adler","doi":"10.1016/j.cgh.2024.06.041","DOIUrl":"10.1016/j.cgh.2024.06.041","url":null,"abstract":"<div><h3>Background & Aims</h3><div>Sleeve gastrectomy (SG) is one of the most commonly performed bariatric procedures worldwide. Gastroesophageal reflux disease (GERD) is a major concern in patients undergoing SG and is a risk factor for Barrett’s esophagus (BE). We conducted a systematic review and meta-analysis to assess the incidence of and analyze predictive factors for post-SG BE.</div></div><div><h3>Methods</h3><div>A comprehensive literature search was conducted in April 2024, for studies reporting on incidence of BE, erosive esophagitis (EE), and hiatal hernia (HH) post-SG. Primary outcomes were post-SG pooled rates of de novo BE, EE, GERD symptoms, proton pump inhibitor use, and HH. Meta-regression analysis was performed to assess if patient and post-SG factors influenced the rates of post-SG BE.</div></div><div><h3>Results</h3><div>Nineteen studies with 2046 patients (79% females) were included. Mean age was 42.2 years (standard deviation, 11.1) and follow-up ranged from 2 to 11.4 years. The pooled rate of de novo BE post-SG was 5.6% (confidence interval, 3.5–8.8). Significantly higher pooled rates of EE (risk ratio [RR], 3.37], HH (RR, 2.09), GER/GERD symptoms (RR, 3.32), and proton pump inhibitor use (RR, 3.65) were found among patients post-SG. GER/GERD symptoms post-SG positively influenced the pooled BE rates, whereas age, sex, body mass index, post-SG EE, and HH did not.</div></div><div><h3>Conclusions</h3><div>Our analysis shows that SG results in a significantly increased risk of de novo BE and higher rates of EE, proton pump inhibitor use, and HH. Our findings suggest that clinicians should routinely screen patients with SG for BE and future surveillance intervals should be followed as per societal guidelines.</div></div>","PeriodicalId":10347,"journal":{"name":"Clinical Gastroenterology and Hepatology","volume":"23 1","pages":"Pages 33-44.e10"},"PeriodicalIF":11.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141765673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Impact of Immigration Status on Gastric Cancer Risk in a Community Hospital in New York City 移民身份对纽约市一家社区医院胃癌风险的影响。

IF 11.6 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Clinical Gastroenterology and Hepatology

Pub Date : 2025-01-01 DOI: 10.1016/j.cgh.2024.08.038

Meredith E. Pittman, Avleen Kaur, Thin Phyu Phyu Aung, Linda A. Lee, Yasutoshi Shiratori

引用次数: 0

Prevalence of Liver Steatosis and Fibrosis in Adults With Primary Hypobetaliproteinemia: Results From the HYPOCHOL Study 原发性低脂血症成人肝脏脂肪变性和纤维化的发病率：HYPOCHOL 研究的结果。

IF 11.6 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Clinical Gastroenterology and Hepatology

Pub Date : 2025-01-01 DOI: 10.1016/j.cgh.2024.06.031

Sarra Smati, Matthieu Wargny, Jerome Boursier, Philippe Moulin, Mathilde Di Filippo, Bertrand Cariou

引用次数: 0

首页上一页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Clinical Gastroenterology and Hepatology

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀